8-K: ARCA biopharma and Oruka Therapeutics Announce Merger to Advance Novel Biologics for Chronic Skin Diseases

ARCA biopharma and Oruka Therapeutics have agreed to merge, creating a company focused on advancing Orukas pipeline of novel biologics for chronic skin diseases, supported by a $275 million private financing.

Summary

• ARCA biopharma and Oruka Therapeutics have entered into a merger agreement, with the combined company focusing on advancing Orukas pipeline of biologics for chronic skin diseases.
• The merger is supported by a $275 million private investment in Oruka, expected to fund operations through 2027.
• Pre-merger ARCA stockholders are expected to own approximately 2.38% of the combined company, while pre-merger Oruka stockholders are expected to own approximately 97.62%.
• ARCA expects to declare a cash dividend to its pre-merger stockholders equal to the amount by which ARCAs net cash exceeds $5 million.
• The combined company will operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ORKA.
• Orukas lead programs, ORKA-001 and ORKA-002, are expected to enter clinical trials in 2025, with initial pharmacokinetic data for ORKA-001 anticipated in the second half of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with a focus on the potential of Orukas pipeline and the financial backing secured through the merger and private financing. The emphasis on best-in-class therapies and long-term value creation suggests a strong positive sentiment from an investment perspective.

Positives

• The merger combines ARCA and Oruka, creating a company focused on a promising pipeline of biologics.
• The $275 million private investment provides substantial funding to support Orukas operations through 2027.
• Orukas lead programs, ORKA-001 and ORKA-002, have the potential to be best-in-class therapies for chronic skin diseases.
• The combined company will have a strong cash position and a clear path to clinical development.
• The merger is expected to provide significant value creation for ARCA stockholders through a cash dividend and the potential of Orukas pipeline.

Negatives

• Pre-merger ARCA stockholders will own a small percentage (approximately 2.38%) of the combined company.
• The merger is subject to customary closing conditions, including stockholder approval and regulatory approvals, which could delay or prevent the transaction from closing.

Risks

• The merger is subject to customary closing conditions, including stockholder approval and regulatory approvals, which could delay or prevent the transaction from closing.
• The private financing may not be completed in a timely manner or at all.
• The combined company may not be able to achieve the expected benefits of the merger.
• The combined company may not be able to successfully develop and commercialize its product candidates.
• The combined company may face competition from other companies in the biopharmaceutical industry.
• The combined company may not be able to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs.

Future Outlook

The combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ORKA, focusing on advancing Orukas pipeline of biologics for chronic skin diseases, with initial clinical data expected in 2025 and operations funded through 2027.

Management Comments

• Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
• We believe that our lead programs, engineered by the world-class team at Paragon, could meaningfully advance the standard of care in psoriasis and related diseases.
• This merger and significant financing is expected to provide resources to build out our operational capabilities and propel our programs into clinical development with focus and efficiency.
• I am excited to support Oruka in their mission to advance the standard of care in plaque psoriasis and other associated diseases.
• We believe that this combination with Oruka is the best path forward for ARCA stockholders.
• We believe that the expected cash dividend and Orukas promising pipeline provides the potential for significant value creation for ARCA stockholders in the nearand long-term.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to advance promising drug candidates. Orukas focus on biologics for chronic skin diseases aligns with the growing market for targeted therapies in dermatology and immunology. The emphasis on long-acting antibodies and disease modification also reflects a shift towards more patient-friendly and potentially curative treatments.

Comparison to Industry Standards

• Orukas lead programs, ORKA-001 and ORKA-002, are designed to compete with existing therapies like Skyrizi (risankizumab) and Bimzelx (bimekizumab), which are leading treatments in the psoriasis market.
• ORKA-001 aims to achieve a longer dosing interval (6 months to 1 year) compared to Skyrizi (quarterly dosing), while potentially delivering higher efficacy based on data from the KNOCKOUT study.
• ORKA-002 is designed to be a best-in-class IL-17A/F inhibitor, targeting a market where dual inhibition has shown superior efficacy compared to IL-17A inhibitors.
• The company is leveraging state-of-the-art antibody engineering, including half-life extension, to achieve infrequent dosing and high antibody exposures, similar to strategies employed by other companies in the biologics space.
• The focus on disease modification and long-term remissions aligns with the growing interest in therapies that can provide more durable benefits beyond symptom management.

Management Changes

Stakeholder Impact

• ARCA stockholders are expected to receive a cash dividend and have the potential for long-term value creation through the combined company.
• Oruka stockholders will own a significant portion of the combined company and benefit from the resources and public listing.
• Patients with chronic skin diseases may benefit from the development of new and potentially more effective therapies.
• Employees of both companies will be part of a larger organization with a focus on advancing innovative treatments.

Next Steps

• File a registration statement on Form S-4 with the SEC.
• Obtain stockholder approval for the merger from both ARCA and Oruka.
• Complete the $275 million private financing.
• Close the merger transaction in the third quarter of 2024.
• Advance ORKA-001 and ORKA-002 into clinical trials in 2025.
• Obtain initial pharmacokinetic data for ORKA-001 in the second half of 2025.

Key Dates

Keywords

Merger, Biologics, Chronic Skin Diseases, Psoriasis, IL-23p19, IL-17A/F, Clinical Trials, Private Financing, Biotechnology, Pharmaceuticals